Role of Sodium Glucose Co-Transporter-2 Inhibitors in Pre-diabetes and Extra-glycemic Effects

  • Hala Ahmadieh Beirut Arab University
  • Nisrine Ghazal American University of Beirut-Medical Center3 Dag Hammarskjold Plaza, 8th Floor, New York, NY 10017, United States
  • Sami Azar American University of Beirut-Medical Center

Abstract

The burden of diabetes mellitus and pre-diabetes has been extensively increasing over the past few years. Selective sodium-glucose co-transporters inhibitors were extensively studied in type 2 diabetes mellitus and were found to have sustained urinary glucose loss, improvement in glycemic control, in addition to their proven metabolic effects. Although they sound to be promising, there is still no clear data regarding their use in the prevention of diabetes, in pre-diabetic individuals, a subset of patients who are at increased risk of development of type II diabetes and its complications. Moreover, sodium-glucose co-transporters inhibitors were found to have multiple extra-glycemic beneficial effects, including weight loss, blood pressure reduction and beneficial effects on the kidneys. Therefore, their use in pre-diabetes is postulated to be beneficial on glucose and metabolic profile and larger studies need to be conducted in this subset of population.


 


 

Published
Oct 12, 2016
How to Cite
AHMADIEH, Hala; GHAZAL, Nisrine; AZAR, Sami. Role of Sodium Glucose Co-Transporter-2 Inhibitors in Pre-diabetes and Extra-glycemic Effects. International Archives of Medicine, [S.l.], v. 9, oct. 2016. ISSN 1755-7682. Available at: <http://imed.pub/ojs/index.php/iam/article/view/1888>. Date accessed: 20 nov. 2017. doi: http://dx.doi.org/10.3823/2129.
Section
Endocrinology

Keywords

SGLT-2 inhibitors, prediabetes, extra-glycemic effects